Abstract: A heart valve prosthesis for replacing a native atrioventricular valve of the heart. The prosthesis includes a housing component that is configured to be radially expandable and compressible between a radially compressed state and a radially expanded state to engage structure of the native atrioventricular valve to fix the housing component relative to the native atrioventricular valve. The housing component includes a housing body and an annular sealing element connected to an atrial end of the housing body. The annular sealing element is made of polyester and is reinforced with wire. A valve component is configured to be radially expandable and compressible between a radially compressed state and a radially expanded state within the housing component. The valve component includes a valve body having a valve passage extending therethrough and three leaflets made from pericardium secured to the valve body.

Abstract: A method of treating a heart includes radially expanding a housing component within a native atrioventricular valve. The housing component includes an atrial anchoring mechanism for deployment in the left atrium and ventricular prongs for engagement with native tissue in the left ventricle. The housing component also includes an interior passageway sized for receiving a valve component. After the housing component has been deployed, the valve component is radially expanded within the passageway of the housing component. The valve component includes three leaflets configured for allowing blood to flow from the left atrium to the left ventricle. After expansion within the housing component, the valve component may have an inflow end portion that protrudes above the housing component into the left atrium. The housing component and valve component are preferably collapsible for advancement through a patient's vasculature using one or more catheters.

Abstract: A method of treating a heart includes radially expanding a housing component within a native atrioventricular valve. The housing component includes an atrial anchoring mechanism for deployment in the left atrium and ventricular prongs for engagement with native tissue in the left ventricle. The housing component also includes an interior passageway sized for receiving a valve component. After the housing component has been deployed, the valve component is radially expanded within the passageway of the housing component. The valve component includes three leaflets configured for allowing blood to flow from the left atrium to the left ventricle. After expansion within the housing component, the valve component may have an inflow end portion that protrudes above the housing component into the left atrium. The housing component and valve component are preferably collapsible for advancement through a patient's vasculature using one or more catheters.

Abstract: A method of treating a heart includes radially expanding a housing component within a native atrioventricular valve. The housing component includes an atrial anchoring mechanism for deployment in the left atrium and ventricular prongs for engagement with native tissue in the left ventricle. The housing component also includes an interior passageway sized for receiving a valve component. After the housing component has been deployed, the valve component is radially expanded within the passageway of the housing component. The valve component includes three leaflets configured for allowing blood to flow from the left atrium to the left ventricle. After expansion within the housing component, the valve component may have an inflow end portion that protrudes above the housing component into the left atrium. The housing component and valve component are preferably collapsible for advancement through a patient's vasculature using one or more catheters.

Abstract: A method of treating a heart includes radially expanding a housing component within a native atrioventricular valve. The housing component includes an atrial anchoring mechanism for deployment in the left atrium and ventricular prongs for engagement with native tissue in the left ventricle. The housing component also includes an interior passageway sized for receiving a valve component. After the housing component has been deployed, the valve component is radially expanded within the passageway of the housing component. The valve component includes three leaflets configured for allowing blood to flow from the left atrium to the left ventricle. After expansion within the housing component, the valve component may have an inflow end portion that protrudes above the housing component into the left atrium. The housing component and valve component are preferably collapsible for advancement through a patient's vasculature using one or more catheters.

Abstract: A heart valve prosthesis (100) comprises a housing component (110) and a valve component (130). The housing component (110) comprises a housing body (111) having a housing passage (112) extending therethrough. The housing body (111) is configured to be located in, or adjacent to and communicating with, a native valve orifice (16) of a heart (10) and to engage structure of the heart (10) to fix the housing body (111) in relation to the valve orifice (161). The housing component (111) is collapsible for delivery via catheter (2). The valve component (130) comprises a valve body (131) having a valve passage (132) extending therethrough. The valve body (131) is configured to be fixed within the housing passage (112) with the valve passage (132) extending along the housing passage (112).

Abstract: A rotary pump including an impeller rotatable within a housing. A load is imposed on the impeller as it rotates, in a direction that is substantially parallel to the axis of rotation and wherein the load stabilises the motion of the impeller. The load may be achieved by magnetically biasing the impeller.

Abstract: An axial flow rotary blood pump including an impeller adapted to be magnetically rotated within a housing by the interaction of magnets disposed on or in the impeller and stators disposed on or in the housing. The impeller includes at least one support ring supporting a plurality of blades, and a hydrodynamic bearing that operates at least axially and radially in respect of an axis of rotation of the impeller.

Abstract: A rotary pump including an impeller rotatable within a housing. A load is imposed on the impeller as it rotates, in a direction that is substantially parallel to the axis of rotation and wherein the load stabilizes the motion of the impeller. The load may be achieved by magnetically biasing the impeller.

Abstract: A heart valve prosthesis (100) comprises a housing component (110) and a valve component (130). The housing component (110) comprises a housing body (111) having a housing passage (112) extending therethrough. The housing body (111) is configured to be located in, or adjacent to and communicating with, a native valve orifice (16) of a heart (10) and to engage structure of the heart (10) to fix the housing body (111) in relation to the valve orifice (161). The housing component (111) is collapsible for delivery via catheter (2). The valve component (130) comprises a valve body (131) having a valve passage (132) extending therethrough. The valve body (131) is configured to be fixed within the housing passage (112) with the valve passage (132) extending along the housing passage (112).

Abstract: An axial flow rotary blood pump including an impeller adapted to be magnetically rotated within a housing by the interaction of magnets disposed on or in the impeller and stators disposed on or in the housing. The impeller includes at least one support ring supporting a plurality of blades, and a hydrodynamic bearing that operates at least axially and radially in respect of an axis of rotation of the impeller.

Abstract: An axial flow rotary blood pump including an impeller (5) adapted to be magnetically rotated within a housing by the interaction of magnets disposed on or in the impeller and stators disposed on or in the housing. The impeller includes at least one support ring (2) supporting a plurality of blades (4), and a hydrodynamic bearing (3) that operates at least axially and radially in respect of an axis of rotation of the impeller (5).

Abstract: A device for communicating electric signals across the skin layer (1) of a patient, wherein the device includes: an electrically conductive core (2) capable of forming an EMF flux loop; first (3) and second (4) coils, which are in EMF communication with said electrical conductive core (2) and wherein the first coil (3) is positioned externally to the patient and surrounds at least a first portion of the electrically conductive core (2); and the second coil (4) is implanted beneath or in the skin layer and surrounds at least a second portion of the electrically conductive core.

Abstract: A rotary pump including an impeller rotatable within a housing. A load is imposed on the impeller as it rotates, in a direction that is substantially parallel to the axis of rotation and wherein the load stabilises the motion of the impeller. The load may be achieved by magnetically biasing the impeller.

Abstract: Cephalosporin antibiotics in which the 7.beta.-acylamido group has the structure ##STR1## (where R is thienyl or furyl; R.sup.a and R.sup.b are each selected from hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.3-7 cycloalkyl, phenyl, naphthyl, thienyl, furyl, carboxy, C.sub.2-5 alkoxycarbonyl and cyano, or R.sup.a and R.sup.b together with the carbon atom to which they are attached form a C.sub.3-7 cycloalkylidene or cycloalkenylidene group; and m and n are each 0 or 1 such that the sum of m and n is 0 or 1) exhibit broad spectrum antibiotic activity characterized by particularly high activity against gram negative microorganisms, including those which produce .beta.-lactamases. The compounds, which are syn isomers or exist as mixtures of syn and anti isomers containing at least 90% of the syn isomer, have particularly high in vitro activity against strains of Escherichia coli, Haemophilus influenzae and Proteus organisms; compounds wherein at least one of R.sup.a and R.sup.

Abstract: Cephalosporin antibiotics in which the 7.beta.-acylamido group has the structure ##STR1## (where R is thienyl or furyl; R.sup.a and R.sup.b are each selected from hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.3-7 cycloalkyl, phenyl, naphthyl, thienyl, furyl, carboxy, C.sub.2-5 alkoxycarbonyl and cyano, or R.sup.a and R.sup.b together with the carbon atom to which they are attached form a C.sub.3-7 cycloalkylidene or cycloalkenylidene group; and m and n are each 0 or 1 such that the sum of m and n is 0 or 1) exhibit broad spectrum antibiotic activity characterized by particularly high activity against gram negative microorganisms, including those which produce .beta.-lactamases. The compounds, which are syn isomers or exist as mixtures of syn and anti isomers containing at least 90% of the syn isomer, have particularly high in vitro activity against strains of Escherichia coli, Haemophilus influenzae and Proteus organisms; compounds wherein at least one of R.sup.a and R.sup.

Abstract: The invention provides novel antibiotic compounds which are 7.beta.-acylamidoceph-3-em-4-carboxylic acids, and non-toxic derivatives thereof characterized in that the acylamido group has the structure ##STR1## where R is a hydrogen atom or an organic group and R.sup.a is an etherifying monovalent organic group linked to the oxygen atom through a carbon atom. The compounds are syn isomers or exist as mixtures containing at least 75% of the syn isomer. These antibiotic compounds possess high antibacterial activity against a range of gram positive and gram negative organisms coupled with particularly high stability to .beta.-lactamases produced by various gram negative organisms. The invention is also concerned with the administration of the compounds.

Abstract: The invention provides novel antibiotic compounds which are 7.beta.-acylamidoceph-3-em-4-carboxylic acids, and non-toxic derivatives thereof characterized in that the acylamido group has the structure ##STR1## where R is a hydrogen atom or an organic group and R.sup.a is an etherifying monovalent organic group linked to the oxygen atom through a carbon atom. The compounds are syn isomers or exist as mixtures containing at least 75% of the syn isomer. These antibiotic compounds possess high antibacterial activity against a range of gram positive and gram negative organisms coupled with particularly high stability to .beta.-lactamases produced by various gram negative organisms. The invention is also concerned with the administration of the compounds.

Abstract: The invention provides novel antibiotic compounds which are 7.beta.-acylamidoceph-3-em-4-carboxylic acids, and non-toxic derivatives thereof characterized in that the acylamido group has the structure ##STR1## where R is a hydrogen atom or an organic group and R.sup.a is an etherifying monovalent organic group linked to the oxygen atom through a carbon atom. The compounds are syn isomers or exist as mixtures containing at least 75% of the syn isomer. These antibiotic compounds possess high antibacterial activity against a range of gram positive and gram negative organisms coupled with particularly high stability to .beta.-lactamases produced by various gram negative organisms. The invention is also concerned with the administration of the compounds.